LDL hemoperfusion - A new procedure for LDL apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients

Artificial Organs

Volumn 21, Issue 10, 1997, Pages 1060-1065

  Bosch, T ^a,d   Schmidt, B ^a   Kleophas, W ^b   Otto, V ^c   Samtleben, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Dialyseinstitut Karlstrasse   (Germany)

^c FRESENIUS AG   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biocompatibility; DALI; Direct adsorption of lipoproteins; Hemoperfusion; LDL apheresis

Indexed keywords

ADSORPTION; BLOOD; CHEMICAL ACTIVATION; DISEASES; LIPOPROTEINS; MEDICAL APPLICATIONS; PATIENT TREATMENT;

'CURRENT; ADSORBERS; ANTI-COAGULATION; CLINICAL TRIAL; DALI; DIRECT ADSORPTION OF LIPOPROTEIN; HEMOPERFUSION; LOW DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN APHERESIS; PILOT STUDIES;

BIOCOMPATIBILITY;

ACID CITRATE DEXTROSE; ANTICOAGULANT AGENT; ANTITHROMBIN; BETA THROMBOGLOBULIN; CALCIUM ION; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; ELASTASE; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; THROMBIN;

ADSORPTION; APHERESIS; ARTICLE; ATHEROSCLEROSIS; BIOCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEMOPERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030771167     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1997.tb00443.x     Document Type: Article

References (18)

1. Bosch T. Lipid apheresis: From a heroic treatment to clinical routine practice. Artif Organs 1996;20:414-9.
2. Hombach V, Borberg H, Gadzkowski A, Oette K, Stoffel W. Regression der Koronarsklerose bei familiärer Hypercholesterinämie Ha durch spezifische LDL-Apherese. Dtsch Med Wochenschr 1986;111:1709-15.
3. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishida T, Okamura K, Saito Y, Teramoto T, Yasugi T, Yamamoto A, and Goto Y, for the LARS investigators. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: A multicenter study. Atherosclerosis 1992;95:1-13.
4. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, et al. The HELP Study Group. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invent 1994;24:724-32.
5. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J Clin Res Ed 1985; 291:1671-3.
6. Seidel D. Behandlung schwerster Cholesterinstoffwechselstörungen. Bayer Internist 1995;15:51-4.
7. Bosch T. State of the art of lipid apheresis. Artif Organs 1996; 20:292-5.
8. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17: 640-52.
9. Bosch T, Schmidt B, Kleophas W, Otto V, Gillen C, Passlick-Deetjen J, Gurland HJ. LDL hemoperfusion-A new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with whole human blood. Artif Organs 1997;21:977-82.
10. Klinkmann H, Davison AM, (eds.) Consensus conference on biocompatibility. Nephrol Dial Transplant 1994;9(Suppl 2): 1-186.
11. Bosch T. Low-density lipoprotein hemoperfusion using a modified polyacrylate adsorber: In vitro, ex vivo, and first clinical results. Artif Organs 1996;20:344-5.
12. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Thrombogenicity markers in clinical and ex vivo assessment of membrane biocompatibility. In: Koch KM, Streicher E, eds. Biological reactions within the extracorporeal blood circuit during hemodialysis. Basel: Karger, in Contrib Nephrol 1987; 59:90-8.
13. Gawaz MP, Ward RA. Effects of hemodialysis on platelet-derived thrombospondin. Kidney Int 1991;40:257-65.
14. Henderson LW, Chenoweth D. Biocompatibility of artificial organs: An overview. Blood Purif 1987;5:10-11.
15. Heparin versus citrate in membrane plasma filtration. In: Nosé Y, Kjellstrand C, Ivanovich P (eds.) Progress in Artificial Organs - 1985. Cleveland. OH: IASO Press, 1986.
16. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981;67:223-8.
17. Bosch T, Thiery J, Gurland HJ, Seidel D. Long-term efficiency, biocompatibility and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dial Transplant 1993;8:1350-8.
18. Hörl WH, Schaefer RM, Heidland A. Effect of different dialyzers on proteases and proteinase inhibitors during hemodialysis. Am J Nephrol 1985;5:320-6.